We are live on ! Find out more
SCLN

Sciclone Pharmaceuticals Inc
SCLN

Delisted

SCLN was delisted on the 13th of October, 2017.

134 hedge funds and large institutions have $860M invested in Sciclone Pharmaceuticals Inc in 2015 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 49 increasing their positions, 56 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

22,000% more call options, than puts

Call options by funds: $221K | Put options by funds: $1K

124% more capital invested

Capital invested by funds: $383M → $860M (+$477M)

8% less funds holding

Funds holding: 146134 (-12)

13% less repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 56

44% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 27

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
134
Holders Change
-12
Holders Change %
-8.22%
% of All Funds
3.74%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
15
Increased
49
Reduced
56
Closed
27
Calls
$221K
Puts
$1K
Net Calls
+$220K
Net Calls Change
-$295K
Name Holding Trade Value Shares
Change
Change in
Stake
RhumbLine Advisers
76
RhumbLine Advisers
Massachusetts
$328K +$18.3K +2,136 +5%
ProShare Advisors
77
ProShare Advisors
Maryland
$299K -$24.2K -2,831 -6%
SEI Investments
78
SEI Investments
Pennsylvania
$297K +$365K +42,660 +26,497%
NFA
79
Nationwide Fund Advisors
Ohio
$292K
MLICM
80
Metropolitan Life Insurance Company (MetLife)
New York
$273K -$8.26K -964 -2%
DC
81
Davenport & Co
Virginia
$271K +$141K +16,500 +73%
UBS AM
82
UBS AM
Illinois
$257K
Federated Hermes
83
Federated Hermes
Pennsylvania
$257K +$49.3K +5,753 +18%
Public Employees Retirement Association of Colorado
84
Public Employees Retirement Association of Colorado
Colorado
$247K
Bank of America
85
Bank of America
North Carolina
$224K -$59.1K -6,905 -18%
Barclays
86
Barclays
United Kingdom
$220K +$306K +35,680 +3,543%
QI
87
Quotient Investors
New York
$214K -$398K -46,493 -60%
CS
88
Credit Suisse
Switzerland
$212K -$1.34M -156,200 -84%
DIA
89
Denver Investment Advisors
Colorado
$211K -$8.97K -1,047 -3%
AIG
90
American International Group
New York
$202K +$291 +34 +0.1%
BCM
91
BlueCrest Capital Management
Jersey
$201K -$291K -34,019 -54%
Ohio Public Employees Retirement System (OPERS)
92
Ohio Public Employees Retirement System (OPERS)
Ohio
$198K +$244K +28,527 New
First Trust Advisors
93
First Trust Advisors
Illinois
$196K +$41.9K +4,895 +21%
VOYA Investment Management
94
VOYA Investment Management
Georgia
$192K -$78.8K -9,197 -25%
Two Sigma Investments
95
Two Sigma Investments
New York
$189K -$1.1M -128,438 -82%
BFM
96
Boothbay Fund Management
New York
$178K +$67.6K +7,893 +44%
DekaBank Deutsche Girozentrale
97
DekaBank Deutsche Girozentrale
Germany
$174K +$4.28K +500 +2%
VRS
98
Virginia Retirement Systems
Virginia
$171K +$13.7K +1,600 +7%
Jacobs Levy Equity Management
99
Jacobs Levy Equity Management
New Jersey
$167K -$149K -17,400 -42%
SCM
100
Stevens Capital Management
Pennsylvania
$145K -$26.5K -3,099 -13%

SCLN Hedge Fund Activity: Q3 2015 in Review

134 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q3 2015, worth a combined $860M — up 124% from $383M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of SCLN and 15 opened new positions — a net loss of 12 holders — while 56 trimmed existing stakes and 49 added.

The largest buyer was Fisher Asset Management, opening a new position worth an estimated $3.41M. The largest seller was Nantahala Capital Management, cutting an estimated $7.65M.

  • 134 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q3 2015, down from 146 in Q2 2015.
  • Funds reported $860M of Sciclone Pharmaceuticals Inc stock for Q3 2015, up 124% quarter-over-quarter.
  • 15 funds opened new Sciclone Pharmaceuticals Inc positions in Q3 2015 and 27 closed out, a net change of -12 holders.
  • The largest Sciclone Pharmaceuticals Inc buyer in Q3 2015 was Fisher Asset Management, an estimated $3.41M added.
  • The largest Sciclone Pharmaceuticals Inc seller in Q3 2015 was Nantahala Capital Management, an estimated $7.65M sold.

Based on aggregated 13F filings for Q3 2015.